OpGen Inc (OPGN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:OpGen Inc (OPGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9834
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, swift detection and analysis of antibiotic resistance, and detection of pathogens in blood cultures. OpGen’s develops products that includes QuickFISH, and PNA FISH products, Acuitas products, and Acuitas Lighthouse informatics. OpGen offers its surveillance products and customized screening services to healthcare providers to protect the hospital biome and optimize patient care. The company sells its products in the US and abroad. OpGen is headquartered in Gaithersburg, Maryland, the US.

OpGen Inc (OPGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OpGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OpGen Inc, Medical Devices Deals, 2012 to YTD 2018 10
OpGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OpGen Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
OpGen Raises USD1.2 Million in Venture Financing 12
Opgen Raises USD1 Million in Venture Financing 13
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 14
OpGen Raises US$2 Million In Venture Financing 15
OpGen Raises Additional US$2.6 Million In Series C Financing 16
OpGen Raises Additional USD1.4 Million in Venture Financing 18
Partnerships 19
OpGen and Hitachi High-Technologies Amends its Agreement to Develop Human Chromosome Mapping Service 19
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 20
OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 21
Life Technologies Enters Into Co-Development Agreement With OpGen 22
OpGen Enters Into Co-Development Agreement With In-Q-Tel 23
Equity Offering 24
OpGen Raises USD12 Million in Public Offering of Units 24
OpGen Raises USD0.1 Million in Equity Offering 26
Opgen Raises USD10 Million in Public Offering of Units 27
OpGen Raises USD5 Million in Private Placement of Shares 28
OpGen Raises USD17 Million in IPO 29
Debt Offering 31
OpGen Raises USD0.5 Million in Debt Financing 31
OpGen Raises USD1.5 Million in Private Placement of 8% Notes 32
OpGen Inc – Key Competitors 33
OpGen Inc – Key Employees 34
OpGen Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Oct 15, 2018: OpGen provides business and preliminary financial update 36
Aug 02, 2018: Opgen announces second quarter 2018 financial results 37
May 08, 2018: OpGen Announces First Quarter 2018 Financial Results 39
Mar 15, 2018: OpGen Announces Fourth Quarter and Full Year 2017 Financial Results 41
Aug 08, 2017: OpGen Reports 2017 Second Quarter Financial Results and Provides Business Update 43
Apr 26, 2017: OpGen Announces 2017 First Quarter Financial Results 45
Mar 23, 2017: OpGen Announces 2016 Fourth Quarter and Year End Financial Results 46
Jan 26, 2017: OpGen Reports Preliminary Fourth Quarter and Full Year 2016 Financial Results 47
Corporate Communications 49
Feb 05, 2018: OpGen Regains Compliance With Nasdaq Listing Requirements 49
Apr 27, 2017: OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors 50
Product News 51
Feb 01, 2018: OpGen Introduces New RUO Rapid Test for Infection Control and Surveillance Studies 51
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
OpGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OpGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OpGen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
OpGen Inc, Medical Devices Deals, 2012 to YTD 2018 10
OpGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
OpGen Raises USD1.2 Million in Venture Financing 12
Opgen Raises USD1 Million in Venture Financing 13
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 14
OpGen Raises US$2 Million In Venture Financing 15
OpGen Raises Additional US$2.6 Million In Series C Financing 16
OpGen Raises Additional USD1.4 Million in Venture Financing 18
OpGen and Hitachi High-Technologies Amends its Agreement to Develop Human Chromosome Mapping Service 19
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 20
OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 21
Life Technologies Enters Into Co-Development Agreement With OpGen 22
OpGen Enters Into Co-Development Agreement With In-Q-Tel 23
OpGen Raises USD12 Million in Public Offering of Units 24
OpGen Raises USD0.1 Million in Equity Offering 26
Opgen Raises USD10 Million in Public Offering of Units 27
OpGen Raises USD5 Million in Private Placement of Shares 28
OpGen Raises USD17 Million in IPO 29
OpGen Raises USD0.5 Million in Debt Financing 31
OpGen Raises USD1.5 Million in Private Placement of 8% Notes 32
OpGen Inc, Key Competitors 33
OpGen Inc, Key Employees 34
OpGen Inc, Subsidiaries 35

List of Figures
OpGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
OpGen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
OpGen Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[OpGen Inc (OPGN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TransGenic Inc (2342):企業の財務・戦略的SWOT分析
    TransGenic Inc (2342) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Vietnam Golf Tourism JSC:企業の戦略・SWOT・財務情報
    Vietnam Golf Tourism JSC - Strategy, SWOT and Corporate Finance Report Summary Vietnam Golf Tourism JSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Flint Hills Resources LLC:企業の戦略的SWOT分析
    Flint Hills Resources LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • PTC Therapeutics Inc (PTCT)-製薬・医療分野:企業M&A・提携分析
    Summary PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and commercializes orally active small molecule therapeutics that target post transcriptional control. The company's pipeline products include an orally administered small-molecule targeted at genetic disorders due to a nonsense mu …
  • Samyang Holdings Corp (000070):企業の財務・戦略的SWOT分析
    Summary Samyang Holdings Corp (Samyang) is a holding company engaged in the development and manufacture of food, pharmaceutical and chemical products. The company produces chemicals such as terephthalic acid, engineering plastics, organic chemicals, resins and other specialty chemicals; food materia …
  • PG&E Corporation (PCG):企業の財務・戦略的SWOT分析
    PG&E Corporation (PCG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Reynard Corporation:企業の戦略・SWOT・財務情報
    Reynard Corporation - Strategy, SWOT and Corporate Finance Report Summary Reynard Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Pilgrim’s Pride Corporation (PPC):企業の財務・戦略的SWOT分析
    Pilgrim's Pride Corporation (PPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • BioLargo Inc (BLGO):企業の財務・戦略的SWOT分析
    Summary BioLargo Inc (BioLargo) is a chemical company that offers solutions for clean water, air and wound care. The company’s products portfolio includes oxidation system, industrial odour control product, skin infection cleansers and iodine dosing system. Its oxidation system contains energised ma …
  • Mesa Laboratories Inc (MLAB):企業の財務・戦略的SWOT分析
    Summary Mesa Laboratories Inc (Mesa) is a medical device company. It manufactures and markets validation and monitoring instruments. The company’s products include mesa biological indicators, DryCal gas flow calibrators, BGI ambient particulate sampling, DialyGuard dialysate meters, SureTorque cap t …
  • Cassava Sciences Inc (SAVA):企業の財務・戦略的SWOT分析
    Cassava Sciences Inc (SAVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • FLSmidth & Co. A/S:企業の戦略・SWOT・財務分析
    FLSmidth & Co. A/S - Strategy, SWOT and Corporate Finance Report Summary FLSmidth & Co. A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mitsubishi Electric Corporation:企業の戦略・SWOT・財務情報
    Mitsubishi Electric Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Electric Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Eurocommercial Properties NV:企業の戦略・SWOT・財務分析
    Eurocommercial Properties NV - Strategy, SWOT and Corporate Finance Report Summary Eurocommercial Properties NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • POSCO:企業のM&A・事業提携・投資動向
    POSCO - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's POSCO Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisin …
  • Armstrong World Industries, Inc:企業の戦略・SWOT・財務情報
    Armstrong World Industries, Inc - Strategy, SWOT and Corporate Finance Report Summary Armstrong World Industries, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Glycotope GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Glycotope GmbH (Glycotope) is a biopharmaceutical company that develops immuno-oncology products for the treatment of various types of cancer. The company’s expression platform offers proprietary technologies such as Glycobody (GET) and GlycoExpress(GEX) that allows the glycosylation of anti …
  • Edwards Lifesciences Corp (EW)-医療機器分野:企業M&A・提携分析
    Summary Edwards Lifesciences Corp (Edwards) is a global medical technology company, which focuses on the development, manufacture and marketing of products and technologies used for the treatment of structural heart disease and critical conditions. It develops and commercializes heart valve products …
  • Altice USA, Inc. (ATUS):企業の財務・戦略的SWOT分析
    Altice USA, Inc. (ATUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • E. Bon Holdings Limited (599):企業の財務・戦略的SWOT分析
    E. Bon Holdings Limited (599) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆